Peer-reviewed Phase 2 Results Inform Ongoing Phase 3/Pivotal Trial of Celeste® in Parkinson’s Disease The Phase 2 study ...

Mean weight loss of up to 12.1% with no observed plateau at 26 weeks in Phase 2 trial in China with oral GLP-1/GIP receptor ...

Study to be conducted by PharmaLegacy, a leading Contract Research Organization The scientific rationale for evaluating ...

The atmospheres of exoplanets have been a focal point of the field lately, with the James Webb Space Telescope taking a look at as many as it can manage. But time on the world's most powerful space ...

Axon Neuroscience's active tau immunotherapy AADvac1 has been selected as the first tau-targeted therapy to enter a ...

On 3 February 2026, NMD Pharma announced topline results from its Phase 2a study of ignaseclant  in Charcot-Marie-Tooth disease Types 1 and 2. NMD Pharma A/S Dan Brennan, SVP Corporate and Commercial ...

Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases ...

Specialty Pharmaceutical business, with more than 30 years of experience across neuroscience, rare disease, and specialty ...

A rapturous response to data published last year for Pelage’s hair loss candidate overwhelmed the biotech. Now, the company ...

February 2025. KDventures AB (Nasdaq Stockholm: KDV) today publishes its Year-end Report January-December 2025. The full report is available on the Company's website. “A stronger financial position ...

H.E. Aseela Abdullah Al Moalla, Director of the Fujairah Environment Authority, highlighted the strategic role of the Emirate ...

SHELTON, CONNECTICUT / ACCESS Newswire / February 12, 2026 / NanoViricides, Inc., a publicly traded company (NYSE ...